Racotumomab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Mouse |
| Target | NGNA ganglioside |
| Clinical data | |
| Trade names | Vaxira |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6476H9922N1712O2048S50 |
| Molar mass | 146133.55 g·mol−1 |
| (what is this?) (verify) | |
Racotumomab[1][2] (trade name Vaxira) is a therapeutic cancer vaccine for the treatment of solid tumors that is currently under clinical development by ReComBio (R and Research in Computational Biology), an international public-private consortium with the participation of the Center of Molecular Immunology at Havana, Cuba (CIM) and researchers from Buenos Aires University and National University of Quilmes in Argentina.[3][4] It induces the patient's immune system to generate a response against a cancer-specific molecular target with the purpose of blocking tumor growth, slowing disease progression and ultimately increasing patient survival.
Racotumomab triggers an immune response against the tumor antigen N-glycolyl (NGc) GM3 (NGcGM3), a type of ganglioside present on the cell surface of malignant cells from lung and breast, melanoma, as well as neuroectodermal pediatric tumors.[5][6][7] Racotumomab has successfully completed a proof-of concept clinical trial in advanced non-small cell lung cancer (NSCLC) and is currently being tested in a large, multinational study for the same indication.[8]
Racotumomab has been approved in two countries, Argentina and Cuba, for the treatment of recurrent or advanced NSCLC, or NSCLC independent of the disease stage when no other standard therapy can be administered.
- ^ World Health Organization(2008) WHO Drug Information
- ^ Pharmaceutical product authorized under special conditions by the Argentine Ministry of Health -Cert.N:57.031
- ^ "Vaxira® | Deteniendo el proceso, prolongando la vida". www.vaxira.com.
- ^ "Consorcio de investigación, desarrollo e innovación". Archived from the original on 2018-03-02. Retrieved 2013-05-17.
- ^ Alfonso M, Díaz A, Hernández AM, Pérez A, Rodríguez E, Bitton R, et al. (March 2002). "An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients". Journal of Immunology. 168 (5): 2523–9. doi:10.4049/jimmunol.168.5.2523. PMID 11859147.
- ^ Scursoni AM, Galluzzo L, Camarero S, Lopez J, Lubieniecki F, Sampor C, et al. (2011). "Detection of N-glycolyl GM3 ganglioside in neuroectodermal tumors by immunohistochemistry: an attractive vaccine target for aggressive pediatric cancer". Clinical & Developmental Immunology. 2011: 245181. doi:10.1155/2011/245181. PMC 3177098. PMID 21941577.
- ^ van Cruijsen H, Ruiz MG, van der Valk P, de Gruijl TD, Giaccone G (June 2009). "Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer". BMC Cancer. 9: 180. doi:10.1186/1471-2407-9-180. PMC 2705377. PMID 19519895.
- ^ "Search of: racotumomab - List Results - ClinicalTrials.gov". clinicaltrials.gov.